Monday, September 22, 2014

Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharma adopts 5-by-5 mantra for future growth

September 16, 2014 by · Leave a Comment 

Tweet Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. “I want to emphasize that this is not guidance, but within five years, we want our dermatology business in Canada to grow from $2-million this year to $50-million, we want to have […]

Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

September 9, 2014 by · Leave a Comment 

Tweet NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. “Our continuum of care includes diagnostics that can be performed at outpatient clinics and by primary care physicians, where […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

Finding the origins of cancer with Rosetta Genomics

Finding the origins of cancer with Rosetta Genomics

August 26, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=z8RTk67NNWg’]

Tweet Taking its name from the Rosetta Stone, which paved the way to decipher ancient Egyptian hieroglyphics, Rosetta Genomics (NASDAQ:ROSG) is unlocking the relevance of microRNA within the human genome to develop next generation diagnostic tests for personalized medicine. “MicroRNAs are master gene regulators of almost every activity in the cell, and when something goes […]

Titan implanting treatments for opioid dependence

Titan implanting treatments for opioid dependence

August 19, 2014 by · Leave a Comment 

Tweet In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick-sized implant of the approved drug, buprenorphine, which eases withdrawal symptoms. “With more than two million people in the U.S. suffering from opioid dependence, there […]

Lorus hopes to start LOR-253 trial in mid-September

Lorus hopes to start LOR-253 trial in mid-September

August 12, 2014 by · Leave a Comment 

Tweet After a corporate refocusing with a new management and clinical development team, Lorus Therapeutics (OTC:LRUSF; TSX:LOR) plans to begin a Phase 1b clinical trial in mid-September of its LOR-253 drug candidate for the treatment of several blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), which is a pre-malignant type of […]

In conversation with Jason Mitakidis

In conversation with Jason Mitakidis

August 5, 2014 by · Leave a Comment 

Tweet As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode of Life Project in 2006 and 2007. Prior to co-founding Cyclica in 2011, he gained several years of research experience in the fields […]

Agile readies new confirmatory pivotal trial of contraceptive patch

Agile readies new confirmatory pivotal trial of contraceptive patch

July 29, 2014 by · Leave a Comment 

Tweet Agile Therapeutics (NASDAQ:AGRX) believes it has addressed the issues raised by the FDA last year about an initial pivotal trial of its Twirla contraceptive patch and is on track to treat the first patient in a new Phase 3 trial in the current quarter. “Following a complete response letter from the FDA in early […]

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

July 22, 2014 by · Leave a Comment 

Tweet XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the […]

Taking a ride across the BBB with biOasis

Taking a ride across the BBB with biOasis

July 15, 2014 by · Leave a Comment 

Tweet biOasis (OTCQX:BIOAF; TSX-V:BTI) believes its Transcend family of technologies holds the key to allow drug therapies to penetrate the blood-brain barrier (BBB) – long considered a Holy Grail of neurological medical research – to treat diseases of the central nervous system. “Our Transcend breakthrough is a naturally occurring physiological transport mechanism that can act […]

Next Page »

Email Newsletters with Constant Contact
Google+